Prostate-specific membrane antigen (PSMA) is a type II membrane glycoprotein with an extensive extracellular domain (44−750 amino acids) and plays a significant role in prostate carcinogenesis and progression [1,2,3,4]. Here, FOLH1 is linked to medical procedure.